Peter Zdziarski: Approval Does Not Mean NovoSeven is 100% Effective or Risk-Free in GT
Peter Zdziarski, Founder and Marketing Director of Glanzmann Thrombasthenia Advocacy Network, shared a post on LinkedIn:
“NovoSeven has been a lifesaving treatment for many people with Glanzmann Thrombasthenia, but I want those in the community to know that it’s important to remember that no medication is perfect.
Like all newer drugs, NovoSeven passed clinical trials, but long-term effects, rare complications, and real-world outcomes still take time to understand fully.
Approval does not mean a treatment is 100% effective or risk-free.
I hope that when adverse events or unexpected outcomes occur, Novo Nordisk thoroughly investigates them and shares those findings publicly. The GT community benefits from transparency, whether the results are positive or negative.
I always say:
Read the fine print, no matter how long or small; ask questions; and understand both the benefits and risks of any treatment you use.
The more we learn, the better care future GT patients will receive.”
Other posts featuring Peter Zdziarski on Hemostasis Today.
-
Oct 19, 2026, 19:44Where You Live Should not Determine Whether You Receive Care – World Federation of Hemophilia
-
Oct 19, 2026, 19:42Belen Bianco: Prevention, Early Suspicion and an Interdisciplinary Approach Save Lives
-
Oct 19, 2026, 19:40Christina Chrysohoou: Catheter-Based LAAC vs OAC for Stroke Prevention in Atrial Fibrillation
-
Oct 19, 2026, 19:38Matthew Flick: A Two-Day Research Meeting on Fibrinogen, Hemostasis and Thrombosis
-
Oct 19, 2026, 19:37Hayat Saeed: Excited to Share Our Publication on the FGL1–Hepcidin Axis in Iron Homeostasis and Disease
-
Oct 19, 2026, 19:08IPAW 2026 Comes to a Close, but the Work Continues – PPTA
-
Oct 19, 2026, 17:44Paul Riley: Moderating a Webinar on Anticoagulation Monitoring
-
Oct 19, 2026, 16:36Christopher Pittman: Blood Clot Prevention Cannot End at Hospital Discharge
-
Oct 19, 2026, 16:13Javier M. Floren: When Immune Cells Move With Their Environment